Biodel, Inc. is a United States-based company that develops drug delivery technologies. The Company develops and patents a novel drug delivery platform called Viadel. Its technology is applicable to a range of peptides, proteins and other macromolecules. Its current focus is on developing Viadel for the delivery of insulin to treat patients with Type 1 and Type 2 diabetes. The Company develops novel forms of insulin and other peptide hormones for use in treating diabetes and its complications, including hyperglycemia, hypoglycemia, cardiovascular complications and weight control.